Carbon Biosciences

Executive Summary

Carbon Biosciences is a private biotechnology company founded in 2019 and headquartered in Waltham, Massachusetts. The company is pioneering novel gene therapies based on its proprietary parvovirus vector platform, which is designed to overcome key limitations of conventional viral vectors, such as adeno-associated viruses (AAVs). Specifically, Carbon's platform enables larger genetic payloads (up to ~8–9 kb) and offers improved tissue-targeting capabilities, broadening the range of treatable genetic diseases. The lead program targets cystic fibrosis (CF), a monogenic lung disorder caused by mutations in the CFTR gene. By delivering a functional copy of CFTR, Carbon's therapy aims to address the root cause of disease, potentially offering a one-time curative option for patients regardless of mutation type.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead CF program30% success
• Q2 2026Presentation of preclinical proof-of-concept data for second pipeline indication70% success
• TBDSeries A or B financing round to support clinical development50% success